Alpha 2.0
Login Register
» Articles » PMID: 8695284

Beneficial Effects of Octreotide in a Patient with a Metastatic Paraganglioma

Overview
Journal Eur J Cancer
Specialty Oncology
Date 1996 Apr 1
PMID 8695284
Citations 7
Authors
F Tenenbaum
M Schlumberger
J Lumbroso
C Parmentier
Affiliations
Soon will be listed here.
Citing Articles

The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives.

Bracigliano A, Marretta A, Guerrera L, Simioli R, Clemente O, Granata V Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543140 PMC: 10975789. DOI: 10.3390/ph17030354.

Metastatic paraganglioma.

Harmsworth D, Mallia A, DeGaetano J, Cassar P BMJ Case Rep. 2023; 16(1.

PMID: 36653043 PMC: 9853136. DOI: 10.1136/bcr-2022-252449.

Metastatic Malignant Paraganglioma Presenting as a Neck Mass Treated with Radiolabeled Somatostatin Analog.

Jehangir W, Karabachev A, Tsao J, Anker C, Garapati S, Kikut J Case Rep Oncol Med. 2021; 2021:8856167.

PMID: 34211793 PMC: 8205574. DOI: 10.1155/2021/8856167.

Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks.

Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Rubino M J Clin Med. 2021; 10(1).

PMID: 33383673 PMC: 7795591. DOI: 10.3390/jcm10010088.

Role of Ga-DOTATATE PET/CT in a Case of -Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide.

Jha A, Patel M, Baker E, Gonzales M, Ling A, Millo C Nucl Med Mol Imaging. 2020; 54(1):48-52.

PMID: 32206131 PMC: 7062954. DOI: 10.1007/s13139-019-00629-3.